JP2024542943A - 光線力学的療法のための局所用組成物および方法 - Google Patents

光線力学的療法のための局所用組成物および方法 Download PDF

Info

Publication number
JP2024542943A
JP2024542943A JP2024523204A JP2024523204A JP2024542943A JP 2024542943 A JP2024542943 A JP 2024542943A JP 2024523204 A JP2024523204 A JP 2024523204A JP 2024523204 A JP2024523204 A JP 2024523204A JP 2024542943 A JP2024542943 A JP 2024542943A
Authority
JP
Japan
Prior art keywords
composition
skin
topical composition
vehicle
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542943A5 (https=
Inventor
サンガビ，プラディープ
ランダール，スコット
ジン，シャオピン
ハジケジアン，ブレンデン・ビー
ザディコヴィッツ，ジェルジ
アブダルハフォル，ヘイダル
ハク，ツァヌワ
Original Assignee
サン ファーマシューティカル インダストリーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サン ファーマシューティカル インダストリーズ，インコーポレイテッド filed Critical サン ファーマシューティカル インダストリーズ，インコーポレイテッド
Publication of JP2024542943A publication Critical patent/JP2024542943A/ja
Publication of JP2024542943A5 publication Critical patent/JP2024542943A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024523204A 2021-10-19 2022-10-19 光線力学的療法のための局所用組成物および方法 Pending JP2024542943A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257175P 2021-10-19 2021-10-19
US63/257,175 2021-10-19
PCT/IB2022/060058 WO2023067519A1 (en) 2021-10-19 2022-10-19 Topical compositions and methods for photodynamic therapy

Publications (2)

Publication Number Publication Date
JP2024542943A true JP2024542943A (ja) 2024-11-19
JP2024542943A5 JP2024542943A5 (https=) 2025-10-20

Family

ID=84245894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523204A Pending JP2024542943A (ja) 2021-10-19 2022-10-19 光線力学的療法のための局所用組成物および方法

Country Status (7)

Country Link
US (2) US20230131170A1 (https=)
EP (1) EP4419074A1 (https=)
JP (1) JP2024542943A (https=)
AU (1) AU2022369135A1 (https=)
CA (1) CA3235710A1 (https=)
IL (1) IL312286A (https=)
WO (1) WO2023067519A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860807T3 (es) 2015-10-15 2021-10-05 Dusa Pharmaceuticals Inc Iluminador ajustable para terapia y diagnóstico fotodinámicos
US10357567B1 (en) 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy
JP2025537694A (ja) * 2022-11-04 2025-11-20 サン ファーマシューティカル インダストリーズ，インコーポレイテッド 光線力学的療法の方法
WO2025046471A1 (en) * 2023-08-28 2025-03-06 Sun Pharmaceutical Industries, Inc. Photodynamic therapy in combination with an hedgehog pathway inhibitor for use in treating non-melanoma skin cancer
WO2025235557A2 (en) 2024-05-07 2025-11-13 Sun Pharmaceutical Industries, Inc. Photodynamic therapy illuminator and photodynamic therapy methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5954703A (en) 1997-10-31 1999-09-21 Dusa Pharmaceuticals, Inc. Method and apparatus for applying 5-aminolevulinic acid
US6223071B1 (en) 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
EP3143986A1 (en) * 2015-09-21 2017-03-22 Zimmer MedizinSysteme GmbH Hydrophilic gel for topical delivery of 5-aminolevulinic acid and production thereof
ES2860807T3 (es) 2015-10-15 2021-10-05 Dusa Pharmaceuticals Inc Iluminador ajustable para terapia y diagnóstico fotodinámicos
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
US10814114B2 (en) 2015-12-08 2020-10-27 Dusa Pharmaceuticals, Inc. Method and apparatus for applying a topical solution
US10357567B1 (en) * 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy

Also Published As

Publication number Publication date
US20230131170A1 (en) 2023-04-27
IL312286A (en) 2024-06-01
CA3235710A1 (en) 2023-04-27
US20250009884A1 (en) 2025-01-09
WO2023067519A1 (en) 2023-04-27
EP4419074A1 (en) 2024-08-28
AU2022369135A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
JP2024542943A (ja) 光線力学的療法のための局所用組成物および方法
Morton et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications–actinic keratoses, Bowen's disease and basal cell carcinomas
JP7734222B2 (ja) 皮膚障害に対する光線力学的治療方法
RU2444385C2 (ru) Способ фотодинамической терапии для лечения целлюлитов и косметического использования
KR101717792B1 (ko) 히알루론산, 글루코사민 또는 알란토인을 포함하는 산화성의 광활성화된 피부 회춘용 조성물
Charakida et al. Phototherapy in the treatment of acne vulgaris: what is its role?
Chen et al. Successful treatment of oral verrucous hyperplasia with topical 5-aminolevulinic acid-mediated photodynamic therapy
Yu et al. Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion
JP2019123708A (ja) 光線力学療法のための局所用組成物、閉塞性ドレッシング材、それを用いたキット、光線力学療法材料、および光線力学療法のための方法
Moy et al. Photodynamic therapy for photodamage, actinic keratosis, and acne in the cosmetic practice
Zeitouni et al. A retrospective review of pain control by a two‐step irradiance schedule during topical ALA‐photodynamic therapy of non‐melanoma skin cancer
Wojewoda et al. Optimizing treatment of acne with photodynamic therapy (PDT) to achieve long-term remission and reduce side effects. A prospective randomized controlled trial
JP2017503785A (ja) 座瘡のパルス光力学的処置
Ramirez et al. Single visit PDT for basal cell carcinoma–A new therapeutic protocol
Fien et al. Photodynamic therapy for non-melanoma skin cancer
US20100255080A1 (en) Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
Yang et al. Improve efficacy of topical ALA-PDT by calcipotriol through up-regulation of coproporphyrinogen oxidase
US20080146666A1 (en) Method of treatment of skin
JP2006514567A (ja) 発毛
Yang et al. Topical methotrexate pretreatment enhances the therapeutic effect of topical 5-aminolevulinic acid-mediated photodynamic therapy on hamster buccal pouch precancers
RU2398607C1 (ru) Способ терапии фоновых предраковых, злокачественных и метастатических заболеваний
Gu et al. Light-emitting diodes for healthcare and well-being
MX2015000429A (es) Composiciones farmaceuticas para el suministro topico de fotosesibilizadores y usos de los mismos.
US20230035733A1 (en) Management of dermal neurofibromatosis lesions
Taub 5-aminolevulinic acid: acne vulgaris

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251009